What is EBS's current stock price?

As of now, EBS is trading at $10.99, with a daily change of +0.27%.

Market Overview Trending Stocks Stock Screener Trade Insights

Top Rated Stocks Most Active Stocks Top Potential Stocks Top Momentum Stocks Leaderboard

About Us Log In Sign Up Plans & Pricing Contact Us Terms of Use Privacy Policy

Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist

EBS Stock Analysis & IQ Rating | Emergent Biosolution

EBS

Emergent Biosolution

$10.99

+$0.03 | +0.27%

Set Alerts

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

Headlines

52W High

$14.06

MKT CAP

$577.19M

52W Low

$4.02

VOL

$1.46M

P/E Ratio

8.49

AVG VOL

$895.47K

RSI

39.16

TREND

Sideways

EBS Stock IQ

Login to see Emergent Biosolution (EBS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

EBS Target Price

Login to display

Strengths

EBS Rewards

Earnings are forecast to grow

EBS Rewards

Upgraded on attractively valued

EBS Rewards

Trading below its fair value

Risk Analysis

EBS Risk Analysis

Investors losing their confidence

EBS Price Performance

$12.42 (-11.51%)

$9.66 (+13.77%)

$8.71 (+26.18%)

$10.69 (+2.81%)

1year

6month

3month

1month

EBS Risk Level

EBS has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

EBS Analysts Opinion

EBS overall standing based on key factors, offering insights into analysts perspectives and market expectations.
menu Hover over the category for more information

EBS Analysts Opinion

EBS Analysts opinion is negative and it remained unchanged from the past 3 months

EBS Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

68%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

EBS Street Sentiment

EBS Street Sentiment is bullish and have positive views on the near-term outlook

EBS Performance Sentiment

Sentiments overview associated with EBS events and the stock performance.

68%

27%

Positive

Negative

15 out of 22
events present

6 out of 22
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$12.54

Resistance
Price

$11.35

Current Price Range

$13.90

Show methods +

Linked to EBS

IQ

Close Price

Change

CING

3.50

5.61

+3.13%

VKTX

3.92

33.91

+6.38%

SNY

3.84

46.59

-1.85%

COCP

3.50

1.11

0.00%

WVE

4.48

13.66

-2.95%

Recently Viewed

Close Price

Change

EBS

Emergent Biosolution

10.99

+0.27%

GMAB

Genmab A/S ADS

32.25

-4.73%

ATNI

ATN International In

22.53

+1.81%

IDR

Idaho Strategic Resources

44.36

-4.15%

NTB

Bank of N.T.

50.00

-0.54%

EBS Latest Analysis +

Emergent BioSolutions (EBS) Receives a New Order from US Department of War.

Fri Jan 16, 2026

$10.99 | +0.27%

Activity

Dirty Vaccines Clean Cash: Emergent Ex-CEO Sued For Insider Trading. EBS) stock rose .On Thursday New York Attorney General former chief executive James said Kramer used nonpublic information while setting up sales of Emergent stock.The state also announced a settlement with Emergent over approval of the trading plan.The company agreed to pay $900000 in penalties to New York.Emergent also agreed to strengthen executive stock-trading controls and policies.In summer 2020 Emergent signed two manuf

Fri Jan 16, 2026

$10.99 | +0.27%

Activity

Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.

Wed Jan 14, 2026

$12.54 | +3.04%

Activity

Emergent Vision Technologies releases eSDK Pro Software Development Kit to help engineers deploy vision systems faster. VANCOUVER BC Jan. 14 2026 /PRNewswire/ -- Emergent Vision Technologies a leader in high-speed GigE vision cameras and imaging solutions today announced the release of eSDK Pro Software Development Kit (SDK). eSDK Pro is an advanced software development kit designed to help engineers...

Wed Jan 14, 2026

$12.54 | +3.04%

Activity

Emergent BioSolutions: FDA Approves SNDA For NARCAN Carrying Case . (RTTNews) - Emergent BioSolutions (EBS) announced that the FDA has approved its supplemental New Drug Application for over-the-counter NARCAN Nasal Spray to be packaged in a new carrying case which includes two blister packs. The company said the NARCAN carrying case will be mad

Wed Jan 14, 2026

$12.54 | +3.04%

Activity

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal a Significant Step Achieved Toward its Multi-year Transformation. GAITHERSBURG Md. Jan. 12 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions Inc. (NYSE:) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand.This significant milestone reflects strong progress in improving our overall financial/cash position enhancing our financial fle

Mon Jan 12, 2026

$12.39 | -4.51%

Activity

Potential

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026. – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 –– Preliminary Unaudited Full Year 2025 Total Revenue and United States XPOVIO®. (selinexor) Net Product Revenue Expected to be Approximately ) a commercial-stage pharmaceutical

Mon Jan 12, 2026

$12.39 | -4.51%

Activity

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the United States Department of War in 2026. GAITHERSBURG Md. Jan. 08 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the United States Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergents existing indefinite-delivery/indefinite-quantity

Thu Jan 8, 2026

$13.36 | -3.95%

Activity

ARWR: Encouraging Early Data for Obesity Programs. By Business UpdateEncouraging Early Data for Obesity ProgramsOn January 6 2026 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced preliminary results for the companys investigational treatments for obesity ARO-INHBE and ARO-ALK7. The company also held a webinar to discuss the results. The slides and the webinar can be accessed here. The data showed that ARO-INHBE both as a monotherapy and in combination with tirzepatide led to reductions in

Wed Jan 7, 2026

$13.90 | +5.70%

Activity

FAQ About EBS Stock Insights

What is EBS current stock price?

What are EBS stock strengths?

What is EBS Risk Level?

What is EBS market cap and volume?

What is EBS current Stock IQ?

Should I buy EBS stock right now?

Is EBS a Strong Buy right now?

What does a 'Strong Buy' rating mean for EBS?

What does a 'Strong Sell' rating mean for EBS?

What factors influence EBS's Stock IQ?

Explore our EBS Stock insights

In-Depth Market Analysis and Trends
Expert Insights on Market Dynamics
Tailored EBS Stock Strategies
Effective Risk Management

FIND US ON

Receive our EBS Daily Alerts

Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts

Market Trends

Stay ahead of the market

Market trends

Investment tips

Market analysis service

Investment Insights

Future potential

Informed investment decisions

Investment analysis

IInvestment strategies

Stock Analysis

In-depth stock analysis

Performance analysis

Stock market insights

Financial trends analysis

EBS

Emergent Biosolution

Set Alerts

Current Price

$10.99

+$0.03 | +0.27%

52W High

$14.06

MKT CAP

$577.19M

52W Low

$4.02

VOL

$1.46M

P/E Ratio

8.49

AVG VOL

$895.47K

RSI

39.16

TREND

Sideways

Overview

Comments

Insights

Risks

Rating

Chart

Analysts

Street

Sentiment

EBS Stock IQ

Login to unlock Emergent Biosolution (EBS) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid

Target Price

Login to display

Stock Insights

Strengths

EBS Rewards

Earnings are forecast to grow

EBS Rewards

Upgraded on attractively valued

EBS Rewards

Trading below its fair value

Risk Analysis

EBS Risk Analysis

Investors losing their confidence

Linked to EBS

Symbol

IQ

Close

Change

CING

3.50

5.61

+3.13%

VKTX

3.92

33.91

+6.38%

SNY

3.84

46.59

-1.85%

COCP

3.50

1.11

0.00%

WVE

4.48

13.66

-2.95%

EBS Street Sentiment

Analysts perspectives on the stock desirability, trend direction and growth potential

68%

Buy
Opinion

Trend
Score

Potential
Score

Consensus Rating

NA

100%

EBS Street Sentiment

EBS Street Sentiment is bullish and have positive views on the near-term outlook

EBS Risk Level

EBS has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.

Click here to check what is your level of risk

Risks Indicators

Beta greater than 1.0

Fair

LOW

HIGH

EBS Performance Sentiment

Sentiments overview associated with EBS events and the stock performance.

68%

27%

Positive

Negative

15 out of 22
events present

6 out of 22
events present

Very Bullish

Bullish

Neutral

Bearish

Very Bearish

Technical Price Levels

Average key support and resistance price levels

Support
Price

$12.54

Resistance
Price

$11.35

Current Price Range

$13.90

Show methods +

EBS Latest Analysis

Emergent BioSolutions (EBS) Receives a New Order from US Department of War.

Fri Jan 16, 2026

$10.99 | +0.27%

Activity

Dirty Vaccines Clean Cash: Emergent Ex-CEO Sued For Insider Trading. EBS) stock rose .On Thursday New York Attorney General former chief executive James said Kramer used nonpublic information while setting up sales of Emergent stock.The state also announced a settlement with Emergent over approval of the trading plan.The company agreed to pay $900000 in penalties to New York.Emergent also agreed to strengthen executive stock-trading controls and policies.In summer 2020 Emergent signed two manuf

Fri Jan 16, 2026

$10.99 | +0.27%

Activity

Emergent BioSolutions Inc. (EBS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow.

Wed Jan 14, 2026

$12.54 | +3.04%

Activity

Emergent Vision Technologies releases eSDK Pro Software Development Kit to help engineers deploy vision systems faster. VANCOUVER BC Jan. 14 2026 /PRNewswire/ -- Emergent Vision Technologies a leader in high-speed GigE vision cameras and imaging solutions today announced the release of eSDK Pro Software Development Kit (SDK). eSDK Pro is an advanced software development kit designed to help engineers...

Wed Jan 14, 2026

$12.54 | +3.04%

Activity

Emergent BioSolutions: FDA Approves SNDA For NARCAN Carrying Case . (RTTNews) - Emergent BioSolutions (EBS) announced that the FDA has approved its supplemental New Drug Application for over-the-counter NARCAN Nasal Spray to be packaged in a new carrying case which includes two blister packs. The company said the NARCAN carrying case will be mad

Wed Jan 14, 2026

$12.54 | +3.04%

Activity

Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal a Significant Step Achieved Toward its Multi-year Transformation. GAITHERSBURG Md. Jan. 12 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions Inc. (NYSE:) announced it made a voluntary prepayment of $100 million under its outstanding term loan facility in late December 2025 using cash on hand.This significant milestone reflects strong progress in improving our overall financial/cash position enhancing our financial fle

Mon Jan 12, 2026

$12.39 | -4.51%

Activity

Potential

Karyopharm Announces Preliminary Unaudited 2025 Revenue and Reiterates Expectation of Delivering Potentially Transformative Phase 3 Data in 2026. – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 –– Preliminary Unaudited Full Year 2025 Total Revenue and United States XPOVIO®. (selinexor) Net Product Revenue Expected to be Approximately ) a commercial-stage pharmaceutical

Mon Jan 12, 2026

$12.39 | -4.51%

Activity

Emergent BioSolutions Receives Delivery Order up to $21.5 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the United States Department of War in 2026. GAITHERSBURG Md. Jan. 08 2026 (GLOBE NEWSWIRE) -- Today Emergent BioSolutions (NYSE: EBS) announced it has received a delivery order valued at up to $21.5 million from the United States Department of War to supply BioThrax® (Anthrax Vaccine Adsorbed) in 2026. This order is under Emergents existing indefinite-delivery/indefinite-quantity

Thu Jan 8, 2026

$13.36 | -3.95%

Activity

ARWR: Encouraging Early Data for Obesity Programs. By Business UpdateEncouraging Early Data for Obesity ProgramsOn January 6 2026 Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) announced preliminary results for the companys investigational treatments for obesity ARO-INHBE and ARO-ALK7. The company also held a webinar to discuss the results. The slides and the webinar can be accessed here. The data showed that ARO-INHBE both as a monotherapy and in combination with tirzepatide led to reductions in

Wed Jan 7, 2026

$13.90 | +5.70%

Activity

Discover EBS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of EBS. We're here to help you make informed investment decisions today.

FIND US ON

Receive our EBS Daily Alerts

Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts

Market trends

In-depth stock analysis

Informed investment decisions

Stock market insights

Stock trading tips

Stock analysis

EBS Stock trends

EBS Stock performance

EBS Stock analysis

EBS investment strategies

Stock strategies

Trading strategies

StocksRunner updates

StocksRunner Insights

Financial Reports

Disclaimer: Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor. The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses. Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.

Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").

This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EBS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

✕

Don't Be a Sheep, Be a StocksRunner

StocksRunner Aggregates The Most Important Headlines Into A Single Stock IQ

Sign up for free and

continue analysing EBS

Signup to Stocksrunner

Already a Member? Click here to Login

Join us on this journey to revolutionize the way you approach investing. Together, let's navigate the stock market with clarity, confidence and cutting-edge intelligence.

EBS Stock Analysis & IQ Rating | Emergent Biosolution

EBS Stock IQ

EBS Target Price

EBS Risk Level

EBS Analysts Opinion

EBS Street Sentiment

EBS Performance Sentiment

Technical Price Levels

Explore our EBS Stock insights

Receive our EBS Daily Alerts

EBS Street Sentiment

EBS Risk Level

Technical Price Levels

Discover EBS Stock analysis and effective trading strategies with StocksRunner.com. Gain valuable insights into stock performance, market trends and the future potential of EBS. We're here to help you make informed investment decisions today.

Receive our EBS Daily Alerts

EBS Alerts